Last reviewed · How we verify
NCT07032961
A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
trial testing Collect epidemiological, diagnostic, and follow-up data after MCG examination. in Gastritis in 10,000 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 24 June 2025 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 October 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- Collect epidemiological, diagnostic, and follow-up data after MCG examination.
Conditions studied
- Gastritis — all drugs for Gastritis →
- Gastric Dysplasia — all drugs for Gastric Dysplasia →
- Gastric Ulcer — all drugs for Gastric Ulcer →
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
45 and older, any sex, with Gastritis or Gastric Dysplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this is to learn about the effectiveness and feasibility of a novel AI- assisted Mobile Capsule Gastroscopy (MCG) system for detecting gastric pathologies in elderly and high-risk populations. The main question it aims to answer is: Can MCG effectively detect gastric pathologies, including common gastric diseases, gastric cancer, and precancerous lesions, in elderly and high-risk individuals at community health centers? Participants will: Epidemiological, diagnostic, and post-MCG follow-up data generated during participants' involvement in the gastric pathologies public screening program will be collected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07032961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastritis
Currently open trials in the same condition.
- NCT06948487 — Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis · recruiting
- NCT06848400 — Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios · NA · recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07032961 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 4 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07032961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing